In conclusion, the present meta-analysis evaluated the long-term efficacy and safety of first-line PD-1 inhibitors plus chemotherapy compared to chemotherapy alone in patients with advanced HER2-negative gastric cancer. Here, ERBB2 is linked to gastric cancer.